LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
🩺 Protocol Summary
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening.
Primary Research Facility: Valleywise Health Medical Center (Phoenix, Arizona)
📋 Basic Study Criteria & Logistics Checklist
0 of 3 CheckedReview these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).
📍 Primary Site Map
Site: Valleywise Health Medical Center — Phoenix, Arizona
📍 All Participating Trial Locations (259 Sites)
Multi-Center TrialThis protocol is enrolling participants across multiple clinical centers:
📄 Print Doctor Discussion Sheet
Preview and print a 1-page summary with 5 tailored questions for your physician.
💰 Clinical Trial Costs & Insurance Coverage
Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.
💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.